Initial data from a phase I study is expected in late 2016. The company plans to initiate a phase III study on ALN-TTRsc02 in 2017, assuming that results from the early-stage studies are positive.

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it has submitted a Clinical Trial Authorization application to the Medicines and Healthcare products ...